Published in J Biol Chem on December 02, 2009
Many players in BCL-2 family affairs. Trends Biochem Sci (2014) 1.64
PUMA binding induces partial unfolding within BCL-xL to disrupt p53 binding and promote apoptosis. Nat Chem Biol (2013) 1.28
Mediation of the antiapoptotic activity of Bcl-xL protein upon interaction with VDAC1 protein. J Biol Chem (2012) 1.11
Telethonin deficiency is associated with maladaptation to biomechanical stress in the mammalian heart. Circ Res (2011) 1.07
Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53. Nat Struct Mol Biol (2011) 1.05
Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity. Cell Death Dis (2014) 1.04
Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis. Proc Natl Acad Sci U S A (2013) 1.02
Direct induction of apoptosis using an optimal mitochondrially targeted p53. Mol Pharm (2012) 0.98
Ligand-independent antiapoptotic function of estrogen receptor-beta in lung cancer cells. Mol Endocrinol (2010) 0.97
TGF-β induces TIAF1 self-aggregation via type II receptor-independent signaling that leads to generation of amyloid β plaques in Alzheimer's disease. Cell Death Dis (2010) 0.95
The DNA-binding domain mediates both nuclear and cytosolic functions of p53. Nat Struct Mol Biol (2014) 0.90
Structural insights into the transcription-independent apoptotic pathway of p53. BMB Rep (2014) 0.89
Dual-site interactions of p53 protein transactivation domain with anti-apoptotic Bcl-2 family proteins reveal a highly convergent mechanism of divergent p53 pathways. J Biol Chem (2013) 0.89
Intermediate progenitors are increased by lengthening of the cell cycle through calcium signaling and p53 expression in human neural progenitors. Mol Biol Cell (2012) 0.84
A conserved mechanism for binding of p53 DNA-binding domain and anti-apoptotic Bcl-2 family proteins. Mol Cells (2014) 0.82
Increased resolution of aromatic cross peaks using alternate 13C labeling and TROSY. J Biomol NMR (2015) 0.80
Delivery of a monomeric p53 subdomain with mitochondrial targeting signals from pro-apoptotic Bak or Bax. Pharm Res (2014) 0.79
A nanobody modulates the p53 transcriptional program without perturbing its functional architecture. Nucleic Acids Res (2014) 0.79
Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL. Cell Death Dis (2016) 0.78
BcL-xL conformational changes upon fragment binding revealed by NMR. PLoS One (2013) 0.78
Solution structure and binding specificity of the p63 DNA binding domain. Sci Rep (2016) 0.77
Yin Yang 1 Promotes Thymocyte Survival by Downregulating p53. J Immunol (2016) 0.76
Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199. PLoS One (2016) 0.76
Orphan Nuclear Receptor NR4A1 Binds a Novel Protein Interaction Site on Anti-apoptotic B Cell Lymphoma Gene 2 Family Proteins. J Biol Chem (2016) 0.75
Nimbolide reduces CD44 positive cell population and induces mitochondrial apoptosis in pancreatic cancer cells. Cancer Lett (2017) 0.75
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem (2004) 112.47
AQUA and PROCHECK-NMR: programs for checking the quality of protein structures solved by NMR. J Biomol NMR (1996) 29.55
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr (2004) 23.86
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Gradient-tailored excitation for single-quantum NMR spectroscopy of aqueous solutions. J Biomol NMR (1992) 17.71
The Xplor-NIH NMR molecular structure determination package. J Magn Reson (2003) 16.23
HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc (2003) 11.65
Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science (2007) 10.60
p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science (2003) 9.94
Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis. Science (1997) 9.73
Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science (2004) 9.52
p53 has a direct apoptogenic role at the mitochondria. Mol Cell (2003) 8.98
BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell (2005) 8.73
Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell (2002) 8.38
X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature (1996) 8.37
Stability of proteins: small globular proteins. Adv Protein Chem (1979) 8.22
Apoptosis: a link between cancer genetics and chemotherapy. Cell (2002) 7.86
Discovering high-affinity ligands for proteins: SAR by NMR. Science (1996) 7.10
A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science (1999) 6.97
Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci U S A (1998) 6.69
How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol (2008) 6.02
Measurement of J and dipolar couplings from simplified two-dimensional NMR spectra. J Magn Reson (1998) 5.83
PUMA couples the nuclear and cytoplasmic proapoptotic function of p53. Science (2005) 5.49
Tunable alignment of macromolecules by filamentous phage yields dipolar coupling interactions. Nat Struct Biol (1998) 4.77
Utilization of site-directed spin labeling and high-resolution heteronuclear nuclear magnetic resonance for global fold determination of large proteins with limited nuclear overhauser effect data. Biochemistry (2000) 4.52
Pharmacological rescue of mutant p53 conformation and function. Science (1999) 3.91
A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J (1995) 3.70
Group epitope mapping by saturation transfer difference NMR to identify segments of a ligand in direct contact with a protein receptor. J Am Chem Soc (2001) 3.47
Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci (2000) 3.00
Detecting folding motifs and similarities in protein structures. Methods Enzymol (1997) 2.63
Small-molecule inhibitor of p53 binding to mitochondria protects mice from gamma radiation. Nat Chem Biol (2006) 2.47
Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario. Cell Death Differ (2006) 2.38
p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res (2008) 2.27
Selective tumor cell targeting using low-affinity, multivalent interactions. ACS Chem Biol (2007) 2.16
WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem (2006) 1.94
Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res (2009) 1.60
Solution structure of p53 core domain: structural basis for its instability. Proc Natl Acad Sci U S A (2006) 1.53
Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR. FEBS Lett (2004) 1.33
Comparative biophysical characterization of p53 with the pro-apoptotic BAK and the anti-apoptotic BCL-xL. J Biol Chem (2007) 1.23
NMR chemical shift perturbation study of the N-terminal domain of Hsp90 upon binding of ADP, AMP-PNP, geldanamycin, and radicicol. Chembiochem (2003) 1.20
Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med (2007) 1.19
Cell biology. Cellular demolition and the rules of engagement. Science (2007) 1.13
p53--a natural cancer killer: structural insights and therapeutic concepts. Angew Chem Int Ed Engl (2006) 1.08
Cooperative binding of p53 to DNA: regulation by protein-protein interactions through a double salt bridge. Angew Chem Int Ed Engl (2005) 0.96
The inoculum effect with gram-negative bacteria in vitro and in vivo. J Antimicrob Chemother (1987) 0.91
2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells. Blood (2009) 0.90
In vitro folding and characterization of the p53 DNA binding domain. Biol Chem (2004) 0.77
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
p53 has a direct apoptogenic role at the mitochondria. Mol Cell (2003) 8.98
Regulation of autophagy by cytoplasmic p53. Nat Cell Biol (2008) 5.97
RGD modified polymers: biomaterials for stimulated cell adhesion and beyond. Biomaterials (2003) 5.34
Activation of integrin function by nanopatterned adhesive interfaces. Chemphyschem (2004) 4.66
p53 opens the mitochondrial permeability transition pore to trigger necrosis. Cell (2012) 4.11
p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. Cancer Res (2008) 3.58
Cell spreading and focal adhesion dynamics are regulated by spacing of integrin ligands. Biophys J (2007) 3.57
Large-scale identification of N-terminal peptides in the halophilic archaea Halobacterium salinarum and Natronomonas pharaonis. J Proteome Res (2007) 3.30
Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med (2005) 3.12
STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo. Gastroenterology (2006) 3.05
The mitochondrial p53 pathway. Biochim Biophys Acta (2008) 2.98
Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology (2003) 2.68
Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther (2012) 2.63
Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J (2007) 2.62
In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol (2004) 2.50
DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med (2002) 2.48
p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res (2008) 2.27
[18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem (2004) 2.20
Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res (2006) 2.17
Two-step methodology for high-yield routine radiohalogenation of peptides: (18)F-labeled RGD and octreotide analogs. J Nucl Med (2004) 2.14
Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood (2011) 2.13
N-methylation of peptides: a new perspective in medicinal chemistry. Acc Chem Res (2008) 2.02
The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. Cell Cycle (2009) 2.00
Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res (2006) 1.96
Perspectives on NMR in drug discovery: a technique comes of age. Nat Rev Drug Discov (2008) 1.95
WT p53, but not tumor-derived mutants, bind to Bcl2 via the DNA binding domain and induce mitochondrial permeabilization. J Biol Chem (2006) 1.94
Lateral spacing of integrin ligands influences cell spreading and focal adhesion assembly. Eur J Cell Biol (2005) 1.93
An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol Cell (2009) 1.90
Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem (2010) 1.87
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A (2011) 1.85
Angiopoietin-2 differentially regulates angiogenesis through TIE2 and integrin signaling. J Clin Invest (2012) 1.85
The RGD motif in fibronectin is essential for development but dispensable for fibril assembly. J Cell Biol (2007) 1.81
Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res (2011) 1.77
p53 contains large unstructured regions in its native state. J Mol Biol (2002) 1.75
Impact of order and disorder in RGD nanopatterns on cell adhesion. Nano Lett (2009) 1.75
Multimeric cyclic RGD peptides as potential tools for tumor targeting: solid-phase peptide synthesis and chemoselective oxime ligation. Chemistry (2003) 1.69
Asymmetric activation of the hsp90 dimer by its cochaperone aha1. Mol Cell (2010) 1.65
A conserved spider silk domain acts as a molecular switch that controls fibre assembly. Nature (2010) 1.65
Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics (2003) 1.63
The N-terminal domain of p53 is natively unfolded. J Mol Biol (2003) 1.62
Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res (2009) 1.60
Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther (2013) 1.60
Impact of local versus global ligand density on cellular adhesion. Nano Lett (2011) 1.58
Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol (2010) 1.57
Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues. Angew Chem Int Ed Engl (2008) 1.48
Carbohydrate-based mimetics in drug design: sugar amino acids and carbohydrate scaffolds. Chem Rev (2002) 1.46
Conformational ordering of biomolecules in the gas phase: nitrogen collision cross sections measured on a prototype high resolution drift tube ion mobility-mass spectrometer. Anal Chem (2014) 1.45
Flt1 acts as a negative regulator of tip cell formation and branching morphogenesis in the zebrafish embryo. Development (2011) 1.44
Protein repellent properties of covalently attached PEG coatings on nanostructured SiO(2)-based interfaces. Biomaterials (2007) 1.44
Induction of cell polarization and migration by a gradient of nanoscale variations in adhesive ligand spacing. Nano Lett (2008) 1.43
Interleukin-6/glycoprotein 130-dependent pathways are protective during liver regeneration. J Biol Chem (2002) 1.42
p73 suppresses polyploidy and aneuploidy in the absence of functional p53. Mol Cell (2007) 1.41
Links between mutant p53 and genomic instability. J Cell Biochem (2012) 1.41
PET Imaging of Integrin αVβ3 Expression. Theranostics (2011) 1.41
Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res (2004) 1.36
The architecture of functional modules in the Hsp90 co-chaperone Sti1/Hop. EMBO J (2012) 1.36
Nuclear degradation of p53 occurs during down-regulation of the p53 response after DNA damage. FASEB J (2002) 1.34
Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood (2013) 1.34
Preclinical studies on the mechanism of action and the anti-lymphoma activity of the novel anti-CD20 antibody GA101. Mol Cancer Ther (2011) 1.33
deltaNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Mol Cell Biol (2003) 1.33
Mitochondrially targeted p53 has tumor suppressor activities in vivo. Cancer Res (2005) 1.33
Nanomolar small molecule inhibitors for alphav(beta)6, alphav(beta)5, and alphav(beta)3 integrins. J Med Chem (2002) 1.31
PET imaging of CXCR4 receptors in cancer by a new optimized ligand. ChemMedChem (2011) 1.28
Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol (2009) 1.27
Ang-2-VEGF-A CrossMab, a novel bispecific human IgG1 antibody blocking VEGF-A and Ang-2 functions simultaneously, mediates potent antitumor, antiangiogenic, and antimetastatic efficacy. Clin Cancer Res (2013) 1.26
Direct reprogramming by oncogenic Ras and Myc. Proc Natl Acad Sci U S A (2013) 1.26
The role of ubiquitination in the direct mitochondrial death program of p53. Cell Cycle (2007) 1.25
Hsp90 is regulated by a switch point in the C-terminal domain. EMBO Rep (2009) 1.24
Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression. J Exp Med (2012) 1.23
Neural guidance molecules, tip cells, and mechanical factors in vascular development. Cardiovasc Res (2008) 1.22
Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res (2008) 1.21
Multiple N-methylation of MT-II backbone amide bonds leads to melanocortin receptor subtype hMC1R selectivity: pharmacological and conformational studies. J Am Chem Soc (2010) 1.20
NMR chemical shift perturbation study of the N-terminal domain of Hsp90 upon binding of ADP, AMP-PNP, geldanamycin, and radicicol. Chembiochem (2003) 1.20
Classic and novel roles of p53: prospects for anticancer therapy. Trends Mol Med (2007) 1.19
Cooperativity in adhesion cluster formation during initial cell adhesion. Biophys J (2008) 1.18
Optimized selective N-methylation of peptides on solid support. J Pept Sci (2006) 1.18
The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction. Angew Chem Int Ed Engl (2002) 1.17
Macrophage migration inhibitory factor MIF interferes with the Rb-E2F pathway. Mol Cell (2005) 1.17
First (18)F-labeled tracer suitable for routine clinical imaging of sst receptor-expressing tumors using positron emission tomography. Clin Cancer Res (2004) 1.15
Tumor Targeting via Integrin Ligands. Front Oncol (2013) 1.15
Hsp12 is an intrinsically unstructured stress protein that folds upon membrane association and modulates membrane function. Mol Cell (2010) 1.14
PET of CXCR4 expression by a (68)Ga-labeled highly specific targeted contrast agent. J Nucl Med (2011) 1.13
Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol (2014) 1.13
Stress-induced p53 runs a transcription-independent death program. Biochem Biophys Res Commun (2005) 1.13
Intrinsic inhibition of the Hsp90 ATPase activity. J Biol Chem (2006) 1.13
Lack of gp130 expression in hepatocytes promotes liver injury. Gastroenterology (2003) 1.12
Detection of mitochondrial localization of p53. Methods Mol Biol (2003) 1.11
The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides. Mol Pharm (2011) 1.10
Transmembrane signal transduction of the alpha(IIb)beta(3) integrin. Protein Sci (2002) 1.10
In support of the BMRB. Nat Struct Mol Biol (2012) 1.09
p53--a natural cancer killer: structural insights and therapeutic concepts. Angew Chem Int Ed Engl (2006) 1.08